This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): QAB149-Asmanex, Indacaterol-Mometasone Combination
Description: QMF149 is a combination of the 24-hour bronchodilator indacaterol (QAB149), targeting beta adrenergic receptors, and the once-daily anti-inflammatory corticosteroid mometasone (Asmanex). QMF149 uses Schering-Plough’s Twisthaler device, a multi-dose dry powder inhaler.
Deal Structure: In August 2006, Schering Plough and Novartis announced an agreement to devlelop and commercialize a QAB149/Asmanex combination product. Under the agreement, the parties will share development costs, and there will be no initial payments by either party. The companies will co-promote the combination therapy worldwide.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was completed in November 2009.
In May 2009, Schering-Plough announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc.
Additional information available to subscribers only: